How to prepare a proposed or final REMS document

What belongs in a proposed REMS package?

FDA’s January 2023 guidance describes the REMS document and materials, plus a separate supporting document. The REMS document states goals, applicable participant and applicant requirements, assessment timetable, materials and statutory elements. The supporting document explains design, implementation and assessment rationale. Write each applicable task as an actor, timing, action and referenced material, and reconcile the final package with the actual FDA decision.

Before you begin

Prescription-drug REMS preparation where the actual product context establishes the need. The applicable statutory elements and program design are product-specific; not every REMS has the same participant requirements.

What you will prepare: A coherent proposed REMS package or a reconciled final version linked to the actual FDA decision.

Collect the decision and design inputs

Identify the product/application, risk to be addressed, actual FDA correspondence and whether the task is initial proposal, amendment or final reconciliation. Obtain the program design, materials and supporting evidence. In the January 2023 guidance, the REMS document expresses goals and requirements; the supporting document explains rationale, implementation and assessment. Keep those roles distinct rather than inserting all scientific justification into participant-facing instructions.

Write requirements as executable participant tasks

For each applicable participant, specify who acts, when, what they do and which actual material they use. Identify applicant responsibilities separately. Include only the elements justified for this REMS; do not add certification or restricted distribution merely because another product has them. Use the applicable FDA standardized language where appropriate, explaining proposed alternatives. Check that every referenced form or training item exists and uses the same terminology.

Reconcile materials, timetable and supporting rationale

Inventory the REMS materials, applicable assessment timetable and statutory elements against the actual design and decision record. Verify technical conformance/SPL requirements with the publishing owner using the current applicable specification. A human-readable document and a technically valid structured file both need content reconciliation. Do not invent an assessment timetable from a generic example or treat proposed materials as approved.

Confirm the final state against the actual decision

When moving from draft to final, compare each requirement and material with the decision correspondence and accepted versions. Record any unresolved difference. In a fictional example, an enrollment form still uses an older participant role after the REMS document changes. Update the dependent material and reassess workflow consistency. If the program has no participant ETASU tasks, do not create empty certification tables just to imitate a template.

Trace every requirement to the material that makes it usable

Draft from the actual program design and agency correspondence. The document should let each relevant participant find what they must do without having to reconstruct the sponsor's scientific rationale. Use a dependency record during preparation; it supplements rather than replaces FDA's recommended participant tables.

The January 2023 guidance recommends organizing participant requirements by role, timing, action and material. When there are no participant requirements to carry out, it says not to include that participant-requirements section. Applicant responsibilities may still apply. Do not manufacture certification or enrollment steps merely because another REMS uses them.

Fictional dependency exercise: the proposed document assigns an action before dispensing, but a companion form asks for confirmation only after dispensing. Identify the intended requirement and obtain the responsible program decision, then reconcile the form, training and operational process. Changing just the sentence in the REMS document leaves the conflicting workflow in place. This example illustrates consistency, not a new dispensing requirement for any particular drug.

Keep the goal distinct from its measure. Sending a letter is an outreach action; a knowledge or behavior objective needs evidence appropriate to that objective. Put design rationale and assessment details in the supporting document without burying participant instructions in scientific discussion. Use the assessment-methodology guide for that evidence design.

The proposed package also needs a complete materials inventory. Guidance IV.A distinguishes appended REMS materials from prescribing information and the Medication Guide, and explains that foreign-language versions are not part of the FDA-approved REMS and are not reviewed by FDA; applicants remain responsible for their completeness and accuracy. Do not label a translation FDA-approved merely because its English source is in an approved program.

Finally, establish the applicable assessment timetable from the actual program. The guidance distinguishes the timetable requirement for NDAs/BLAs from ANDAs, while noting that FDA can require assessments from an ANDA holder. Reconcile all human-readable and structured renditions using the current applicable publishing requirements. Use change correspondence for later modifications, preserving proposed, accepted and implemented states.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides